Roka Bioscience

rokabio.com

Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. The Atlas Detection Assays incorporate advanced molecular technologies and are performed on our sample-in, result-out Atlas System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

CELLARES AND POSEIDA THERAPEUTICS JOIN FORCES TO SPEED UP CELL THERAPY MANUFACTURING

Cellares Corporation | July 16, 2021

news image

Cellares Corporation, a life sciences technology company that has pioneered a revolutionary automated approach to cell therapy manufacturing announced today that Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company that uses proprietary genetic engineering platform technologies to create cell and gene therapeutics with the potential to cure, has joined its Early Access Partnership Program (EAPP). Poseida joins PACT Pharma and academic partner Fred Hutchinson Cancer Research Cen...

Read More

MedTech, Industrial Impact

RIBBON BIOLABS REACHES KEY MILESTONE WITH AUTOMATION OF INFINISYNTHTM PLATFORM FOR COMMERCIAL-SCALE, UNLIMITED LENGTH DNA SYNTHESIS

Ribbon Biolabs | December 21, 2022

news image

Ribbon Biolabs, the DNA synthesis company announced the successful implementation of their innovative InfiniSynthTM platform for the automated assembly of sequence-agnostic and long DNA. Ribbon Biolabs achieved this milestone in collaboration with HighRes® Biosolutions, a leading laboratory automation technology company. The InfiniSynthTM platform enables Ribbon Biolabs to enter the market in 2023 with a highly differentiated approach to providing critical tools for life science research and...

Read More

Cell and Gene Therapy, MedTech

NKGEN BIOTECH, INC. ANNOUNCES FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF SNK02, ALLOGENEIC NK CELL THERAPY PRODUCT CANDIDATE

globenewswire | August 29, 2023

news image

NKGen Biotech, Inc. a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer (“NK”) cell therapies, today announced the first patient has been dosed in a Phase I, multi-center, open-label, dose-escalation study evaluating its cryopreserved investigational allogeneic blood-derived NK cell therapy (“SNK02”). In October 2022, the Food and Drug Administration allowed NKGen&rsq...

Read More

Cell and Gene Therapy

TUNE THERAPEUTICS LAUNCHES WITH PIONEERING EPIGENOMIC CONTROL PLATFORM TO MASTER GENE NETWORKS, TREAT BROAD RANGE OF DISEASES

Tune Therapeutics | December 03, 2021

news image

Tune Therapeutics, a biotechnology company pioneering the creation of epi-therapeutic medicines, launched today with its powerful and precise genetic tuning platform, TEMPO. This cutting-edge technology dials gene expression up or down to desired levels – with the potential to reverse pathways of cancer, genetic disease, and aging by changing cell fate and function at will. "Genetic medicine is at a tipping point. We now understand that the driving...

Read More
news image

Cell and Gene Therapy

CELLARES AND POSEIDA THERAPEUTICS JOIN FORCES TO SPEED UP CELL THERAPY MANUFACTURING

Cellares Corporation | July 16, 2021

Cellares Corporation, a life sciences technology company that has pioneered a revolutionary automated approach to cell therapy manufacturing announced today that Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company that uses proprietary genetic engineering platform technologies to create cell and gene therapeutics with the potential to cure, has joined its Early Access Partnership Program (EAPP). Poseida joins PACT Pharma and academic partner Fred Hutchinson Cancer Research Cen...

Read More
news image

MedTech, Industrial Impact

RIBBON BIOLABS REACHES KEY MILESTONE WITH AUTOMATION OF INFINISYNTHTM PLATFORM FOR COMMERCIAL-SCALE, UNLIMITED LENGTH DNA SYNTHESIS

Ribbon Biolabs | December 21, 2022

Ribbon Biolabs, the DNA synthesis company announced the successful implementation of their innovative InfiniSynthTM platform for the automated assembly of sequence-agnostic and long DNA. Ribbon Biolabs achieved this milestone in collaboration with HighRes® Biosolutions, a leading laboratory automation technology company. The InfiniSynthTM platform enables Ribbon Biolabs to enter the market in 2023 with a highly differentiated approach to providing critical tools for life science research and...

Read More
news image

Cell and Gene Therapy, MedTech

NKGEN BIOTECH, INC. ANNOUNCES FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF SNK02, ALLOGENEIC NK CELL THERAPY PRODUCT CANDIDATE

globenewswire | August 29, 2023

NKGen Biotech, Inc. a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer (“NK”) cell therapies, today announced the first patient has been dosed in a Phase I, multi-center, open-label, dose-escalation study evaluating its cryopreserved investigational allogeneic blood-derived NK cell therapy (“SNK02”). In October 2022, the Food and Drug Administration allowed NKGen&rsq...

Read More
news image

Cell and Gene Therapy

TUNE THERAPEUTICS LAUNCHES WITH PIONEERING EPIGENOMIC CONTROL PLATFORM TO MASTER GENE NETWORKS, TREAT BROAD RANGE OF DISEASES

Tune Therapeutics | December 03, 2021

Tune Therapeutics, a biotechnology company pioneering the creation of epi-therapeutic medicines, launched today with its powerful and precise genetic tuning platform, TEMPO. This cutting-edge technology dials gene expression up or down to desired levels – with the potential to reverse pathways of cancer, genetic disease, and aging by changing cell fate and function at will. "Genetic medicine is at a tipping point. We now understand that the driving...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us